Glenmede Trust’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-9,000
| Closed | -$872K | – | 3205 |
|
|
2019
Q3 | $872K | Hold |
9,000
| – | – | ﹤0.01% | 763 |
|
|
2019
Q2 | $921K | Hold |
9,000
| – | – | ﹤0.01% | 765 |
|
|
2019
Q1 | $1.02M | Buy |
9,000
+8,894
| +8,391% | +$654K | ﹤0.01% | 740 |
|
|
2018
Q4 | $4K | Sell |
106
-12,608
| -99% | -$547K | ﹤0.01% | 2631 |
|
|
2018
Q3 | $693K | Hold |
12,714
| – | – | ﹤0.01% | 823 |
|
|
2018
Q2 | $1.05M | Buy |
12,714
+1,864
| +17% | +$144K | ﹤0.01% | 697 |
|
|
2018
Q1 | $557K | Hold |
10,850
| – | – | ﹤0.01% | 898 |
|
|
2017
Q4 | $557K | Buy |
10,850
+1,456
| +15% | +$105K | ﹤0.01% | 898 |
|
|
2017
Q3 | $837K | Buy |
9,394
+1,092
| +13% | +$82.9K | ﹤0.01% | 797 |
|
|
2017
Q2 | $442K | Hold |
8,302
| – | – | ﹤0.01% | 969 |
|
|
2017
Q1 | $442K | Hold |
8,302
| – | – | ﹤0.01% | 969 |
|
|
2016
Q4 | $414K | Hold |
8,302
| – | – | ﹤0.01% | 990 |
|
|
2016
Q3 | $498K | Buy |
8,302
+3,302
| +66% | +$190K | ﹤0.01% | 935 |
|
|
2016
Q2 | $255K | Hold |
5,000
| – | – | ﹤0.01% | 1123 |
|
|
2016
Q1 | $147K | Hold |
5,000
| – | – | ﹤0.01% | 1239 |
|
|
2015
Q4 | $226K | Hold |
5,000
| – | – | ﹤0.01% | 1150 |
|
|
2015
Q3 | $208K | Buy |
+5,000
| New | +$261K | ﹤0.01% | 1164 |
|
Glenmede Trust's ONCE Position: Q4 2019 in Review
Glenmede Trust sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 9,000 shares — an estimated $872K sold.
Glenmede Trust first reported a position in ONCE in Q3 2015 and held it in 17 quarters. The position peaked at $1.05M in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Glenmede Trust reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Glenmede Trust sold 9,000 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $872K.
- Glenmede Trust first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2015 and held it in 17 quarters.
- Glenmede Trust's Spark Therapeutics, Inc. Common Stock position peaked at $1.05M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Glenmede Trust's 13F filing for Q4 2019, filed 12 Feb 2020.